Merck & Co. stock gains on higher guidance and Wells Fargo conference spotlight

Merck & Co. stock is trading near its 52-week high after Q2 2026 sales growth and a raised full-year outlook, with investors watching management’s appearance at the upcoming Wells Fargo healthcare conference.

Merck & Co., Inc. stock (ISIN US58933Y1055) is trading at 150.78 USD on September 2, 2026 on the New York Stock Exchange, close to its recent 52-week high of 156.92 USD and giving the pharmaceutical group a market capitalization of 369.73 billion USD according to ad-hoc-news data based on market portals.

Guidance raised after Q2 2026 sales growth

According to a corporate news report compiled by ad-hoc-news, Merck & Co. generated revenue of 16.61 billion USD in Q2 2026, an increase of 5 percent versus the prior-year quarter.

On the back of these figures, Merck & Co. lifted its full-year 2026 sales outlook to a range of 66.3 billion USD to 67.3 billion USD, compared with a previous guidance of 65.8 billion USD to 67.0 billion USD as cited in the same report, signaling slightly stronger growth expectations for the rest of the year.

Analyst consensus and valuation backdrop

Analyst data compiled by MarketBeat and summarized in a recent update indicate that Merck & Co. currently carries a consensus rating described as a Moderate Buy, with a consensus price target of 147.60 USD per share, while the shares recently opened at 151.85 USD, suggesting the stock is trading modestly above the average target according to MarketBeat data.

The same MarketBeat overview notes that Merck & Co. reported earnings per share of minus 0.13 USD in the most recent quarter ended in 2026, beating the consensus estimate of minus 0.26 USD by 0.13 USD, on revenue of 16.61 billion USD compared with analyst expectations of 16.37 billion USD, giving the company a net margin of 4.77 percent and a return on equity of 16.73 percent in that period.

Wells Fargo conference appearance in focus

Merck & Co. has confirmed that senior executives will speak at the Wells Fargo 21st Annual Healthcare Conference on September 9, 2026 at 2:15 p.m. Eastern Time, with CFO Caroline Litchfield and Dr. Dean Y. Li, president of Merck Research Laboratories, scheduled to present according to a conference preview published by Guavy.

The company’s own events page also lists the 2026 Wells Fargo Healthcare Conference as part of its investor relations calendar, underlining that Merck & Co. continues to actively engage with the financial community as management discusses strategy, pipeline and financial targets at the Wells Fargo Healthcare Conference entry on Merck’s website.

Key product: Keytruda remains a central earnings driver

Merck & Co. generates a significant share of its pharmaceutical revenue from oncology therapies, with its immune checkpoint inhibitor Keytruda widely regarded as a flagship product in the company’s portfolio and a central driver of growth in recent years, although the latest Q2 2026 report summarized by ad-hoc-news grouped figures at the total sales level rather than breaking out product-level numbers.

Stock near recent high with solid dividend

According to ad-hoc-news, Merck & Co. stock traded at 150.78 USD on September 2, 2026 on the New York Stock Exchange, compared with a 52-week low of 77.58 USD and a 52-week high of 156.92 USD, highlighting a price that is almost double the low of the past year and not far below the high, with the company’s market capitalization estimated at 369.73 billion USD as of the same date.

Dividend data aggregated by MarketBeat and analysis tools on Yahoo Finance indicate that Merck & Co. currently pays a quarterly dividend of 0.85 USD per share, corresponding to an annualized dividend of 3.40 USD and a yield of about 2.2 percent at recent prices, with the next ex-dividend date scheduled for September 15, 2026 and the payment date on October 7, 2026, which adds an income component on top of the share price performance.

Merck & Co. stock key data

• Company: Merck & Co., Inc.
• ISIN: US58933Y1055
• Ticker: MRK
• Trading venue: NYSE
• Price (as of September 2, 2026, 10:49): 150.78 USD
• Market capitalization: 369.73 billion USD (as of September 2, 2026)
• Sector / Industry: Health Care / Pharmaceuticals
• Index membership: S&P 500